Please assess the completion status of the following clinical trial:

Trial Title: ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute, ischemic stroke with first symptoms within 6 hours of beginning treatment~* Baseline NIHSS \> 5~Exclusion Criteria:~* No intracranial, extravascular blood on CT~* Hypertension (systolic \> 185; diastolic \> 105)~* Baseline fibrinogen level \< 100 mg/dL~* Thrombocytopenia (\< 100,000 / mm3)~* Recent (\< 3 days) or anticipated (\< 5 days) use of a thrombolytic agent~* Recent (\< 14 days) or anticipated surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous ancrod (Type: EXPERIMENTAL): Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.
- Intravenous Placebo (Type: PLACEBO_COMPARATOR): Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.

Based on this trial design, predict the completion outcome and termination type (if applicable).